HCA Reports $1.81 Million in 2026-Q1 Lobbying
A HCA Healthcare lobbying record posted November 12 lists $1.81 million in in-house spending for 2026-Q1. Its reported issues include Medicare and Medicaid and health policy.
On this page
The filing posted on November 12
HCA Healthcare reported $1.81 million in in-house federal lobbying for 2026-Q1 in a record posted November 12. The filing is marked 1A and names HCA Healthcare, Inc. as both the company and the client. It lists Medicare/Medicaid and Health Issues as the subjects of the work. The record also names H.R. 2191 and says the lobbying covered the House of Representatives and Senate.
The filing is notable for its reported amount and because it is dated to the first quarter, even though the record's posted date is November 12. Those are separate fields in the disclosure: 2026-Q1 is the period, while November 12 is when this record appeared in SecBot's stored filing view. The distinction matters when reading the record. It describes lobbying reported for a specified quarter, not a statement that HCA spent this amount on November 12.
The available record gives a concise account of the company's reported spending and subject areas. It does not describe the specific positions HCA took on legislation. The bill reference is a filing field, not an explanation of the company's requested outcome. HCA's ticker page and SecBot's lobbying page provide related company and disclosure records: HCA company data and lobbying disclosures.
What the reported amount covers
The $1.81 million figure is reported as HCA's in-house lobbying spend. In-house means the client reported its own lobbying expenses rather than paying an outside firm to lobby on its behalf. It is a disclosure figure for the listed period. It should not be read as a measure of all HCA expenses, a federal payment to HCA, or the financial effect of any policy activity.
The issue labels put the filing in the context of healthcare policy. Medicare/Medicaid and Health Issues are the two subjects stated in the row. The filing identifies H.R. 2191 and both chambers of Congress as related to the reported activity. These fields connect the disclosure to broad policy areas and a named bill, but they do not say which provision was the focus or whether HCA supported or opposed it.
The record does not break the $1.81 million into amounts by issue, bill, or chamber. It also does not provide a time sheet, number of lobbyists, or a description of meetings. There is no basis in this record to allocate a particular share of the spend to Medicare/Medicaid rather than the broader health issue label. Those limits apply even though the disclosure contains a sizable dollar figure and identifies a specific bill.
Other HCA reports in the stored records
SecBot's HCA filing rows show additional records for 2026-Q2 and 2026-Q3. The 2026-Q3 in-house report lists $750,000; accompanying outside-firm filings report $80,000 for Alston & Bird, $60,000 for Mehlman Consulting, and $80,000 for Rubin, Turnbull & Associates. Taken together, those listed Q3 records sum to $970,000. For 2026-Q2, the in-house filing lists $610,000. The three outside-firm records list $80,000, $60,000, and $80,000, for a sum of $830,000.
| Period in stored records | In-house report | Outside-firm reports | Sum of listed rows |
|---|---|---|---|
| 2026-Q1 | $1.81 million | Not itemized here | Not calculated |
| 2026-Q2 | $610,000 | $220,000 | $830,000 |
| 2026-Q3 | $750,000 | $220,000 | $970,000 |
These Q2 and Q3 sums combine the specific rows returned for HCA. They give context for the mix of in-house and outside-firm reports in those periods, but they are not a calculation of company-wide lobbying spend beyond the records shown. The Q1 row featured here stands on its own: the disclosure view does not offer matching Q1 outside-firm rows alongside it in the returned results. Comparing the Q1 amount directly with a complete quarterly total would therefore go beyond the available rows.
A filing timeline, not a policy verdict
The record for 2026-Q1 was posted November 12. Earlier in the returned HCA filing rows, a 2026-Q3 in-house report was posted October 19. Outside-firm reports tied to that quarter appeared October 12 and October 20. The visible dates show that records associated with different reporting periods can appear at different times in the local filing view. They do not by themselves explain the reporting or posting schedule.
Other HCA SEC filing metadata offers corporate context, but not a direct explanation of the lobbying entry. The cache lists a 10-Q filed October 29, along with an 8-K categorized as an earnings release filed October 27. The metadata identifies filing types and dates. It does not establish that either SEC filing was caused by, or related to, the lobbying activity reported for 2026-Q1.
Likewise, the lobbying record does not show that the activity changed the text of H.R. 2191 or produced a government decision. It identifies a bill and agencies involved in the disclosure. It does not document legislative outcomes, agency responses, or the influence of any individual contact. Readers can verify the scope of the stored lobbying rows on the SecBot lobbying page and review the separate company filing context on HCA's stock page.
What the disclosure does not tell us
Lobbying disclosures are useful for following reported activity, but they are not transcripts of the work. This HCA row does not include the names of individual employees involved, the dates of meetings, or the precise language discussed. It does not break out spending among the House, Senate, and the listed policy topics. The filing's amount should therefore be treated as the reported in-house figure for the period, not as a precise valuation of a particular legislative campaign.
The disclosure also does not establish HCA's position on H.R. 2191. A bill appearing in a report means the bill is identified in the filing; it is not enough to conclude that the company endorsed or opposed it. Nor does the record show whether the reported work led to a change in reimbursement rules, a legislative vote, or a financial result for the company. Those outcomes require evidence that is not present in this row.
The Q2 and Q3 sums have a similar limitation. They add the dollar amounts of specific records returned by SecBot for those periods. The sums do not independently certify that every possible record has been captured, and they are not directly comparable to Q1 as a full quarter total because the set of Q1 records shown is incomplete for that comparison. Keeping the scope explicit prevents a listed filing amount from being mistaken for a complete account of all policy spending.
The next record to check
The next useful point in this trail is whether later HCA lobbying rows add disclosures for the same period or describe subsequent reporting periods. The stored data here gives one newly posted 2026-Q1 in-house entry with a clear issue focus and bill reference. It also shows that the available Q2 and Q3 rows mix company spending with outside-firm reports, a distinction that is easy to lose if all amounts are treated as a single kind of expense.
For now, the concrete record is the $1.81 million reported for 2026-Q1, tied to Medicare/Medicaid and Health Issues and associated with H.R. 2191. The record supplies the amount, period, topics, and congressional chambers. It does not supply a position on the bill or an outcome. More SecBot public-disclosure coverage is available at register.